featured
Dr. Warren Heymann: Does the JAK Inhibitor Baricitininb Raise the Bar on Treating Lupus?
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology. J Am Acad Dermatol. 2017;76(4):745-753.
- Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2018 Feb 1. doi: 10.1016/j.jaad.2018.01.018. [Epub ahead of print.]
- Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351-355.
- Choi J, Cooper ML, Staser K, et al. Baricitinib-induced blockade if interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32(11):2483-2494.
- Wallace D, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231.
- Mucke J, Schneider M. Baricitinib for systemic lupus erythematosus. Lancet. 2018;392(10143):190-192.